Search for: "Johnson " Results 7641 - 7660 of 36,429
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
28 Jul 2007, 11:16 pm
  At least that's what I gather from reading Undue Influence: The Epic Battle for the Johnson & Johnson Fortune, by David Margolick. [read post]
16 Mar 2011, 4:40 pm
I’ve written here many times before about the ongoing manufacturing problems at plants owned by McNeil Pharmaceuticals and Johnson & Johnson, which has led to 19 recalls of major over-the-counter drugs such as Tylenol, Motrin and Benadryl. [read post]
1 Dec 2010, 11:35 pm by M. Brandon Smith
., a subsidiary of Johnson & Johnson, recently recalled 93,000 DePuy ASR XL Acetabular Systam Implants and DePuy ASR Hip Resurfacing System implants globally. [read post]
5 Nov 2010, 3:43 pm
Johnson & Johnson isn't the only drug manufacturer having persistant problems with off-smelling medications that require recalls. [read post]
6 Oct 2010, 3:15 am by Bob Kraft
The Los Angeles Times reports, “The head of pharmaceuticals giant Johnson & Johnson, testifying on the massive recall of its widely used children’s pain relievers, admitted Thursday that ‘we did not maintain our high quality standards,’” and consequently, “children do not have access to our important medicines,” Chief Executive William C. [read post]
17 Nov 2014, 3:23 pm by iymanstrawder
A Tylenol liver failure lawsuit has been filed against Johnson & Johnson’s subsidiary, McNeill-PPC, alleging that the company violated consumer protection laws and failed to warn consumers of the grave side effects of Tylenol. [read post]
29 Apr 2010, 2:06 am by Ben Vernia
., two subsidiaries of Johnson & Johnson, have agreed to pay $81 million to settle charges brought in two whistleblower suits that they violated the False Claims Act by promoting Topamax for off-label (unapproved) uses. [read post]
13 Aug 2012, 10:35 am
I really don't think DePuy/Johnson & Johnson are going to be racing to the courthouse steps to try these cases. [read post]
24 Jun 2024, 1:01 pm by Sadie Mayhew
Johnson & Johnson subsidiary Janssen Products, LP, was found liable for the illegal off-label promotion and marketing of its HIV/AIDS-treatment drugs, Prezista and Intelence. [read post]
7 Aug 2017, 7:40 am by jromDLT
The Ethicon Physiomesh, a commonly used hernia repair product, was voluntarily taken off the market by its manufacturer Ethicon, a subsidiary of Johnson and Johnson. [read post]
26 May 2008, 12:20 pm
It’s an issue in drug cases, but it’s also now an issue in white collar case, as Kerri Kaley, a former Johnson & Johnson saleswoman, and her husband face charges of selling unwanted surgical supplies on the gray market. [read post]
13 Jun 2011, 4:30 am by Laura Simons
., a Johnson & Johnson subsidiary, under the state’s Unfair Trade Practices Act for deceptive marketing of its anti-psychotic drug, Risperdal. [read post]
31 Mar 2011, 1:35 pm
Although Johnson & Johnson and DePuy Orthopaedics, Inc. have not recalled the DePuy Pinnacle Acetabular Cup System, the US Food and Drug Administration says that it has received reports indicating similar problems as those involving the DePuy ASR hip implants, which were recalled last year. [read post]
15 Jul 2012, 7:00 pm
Johnson & Johnson revealed last week that it intends on providing more corporate oversight of its drug manufacturing and marketing practices. [read post]
16 Jul 2012, 1:01 pm by Brenda Fulmer
You may recall we reported on June 4 that Ethicon, a division of Johnson & Johnson (J&J), announced it was removing four synthetic vaginal meshes from the market – all fall under the Gynecare division – the TVT Secur, Prosima, Prolift and the Prolift+M. [read post]
4 Apr 2013, 8:48 am by Cal Warriner
So this latest warning from healthcare giant Johnson & Johnson is especially troublesome. [read post]
9 Mar 2017, 9:24 am by Noble McIntyre
Specifically, Ethicon Physiomesh (manufactured by Johnson + Johnson) and Atrium C-Qur (pronounced “secure”) have been recalled, but for different reasons. [read post]
15 Jul 2012, 7:00 pm
Johnson & Johnson revealed last week that it intends on providing more corporate oversight of its drug manufacturing and marketing practices. [read post]